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Virus evolutionA crucial step in the arenavirus life cycle is the proteolytic processing of the viral envelope glycoprotein
precursor (GPC) by the cellular proprotein convertase (PC) subtilisin kexin isozyme-1 (SKI-1)/site-1 protease
(S1P). Here we conducted a systematic and quantitative analysis of SKI-1/S1P processing of peptides derived
from the recognition sites of GPCs of different Old World and NewWorld arenaviruses. We found that SKI-1/
S1P showed a strong preference for arenaviral sequences resembling its autoprocessing sites, which are
recurrent motifs in arenaviral GPCs. The African arenaviruses Lassa, Mobala, and Mopeia resemble the SKI-1/
S1P autoprocessing C-site, whereas sequences derived from Clade B New World viruses Junin and Tacaribe
have similarities to the autoprocessing B-site. In contrast, analogous peptides derived from cellular SKI-1/S1P
substrates were remarkably poor substrates. The data suggest that arenavirus GPCs evolved to mimic SKI-1/
S1P autoprocessing sites, likely ensuring efﬁcient cleavage and perhaps avoiding competition with SKI-1/S1P's
cellular substrates.University Hospital Center and
. Fax: +41 21 314 4060.
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
The arenaviruses are a large and diverse family of enveloped RNA
viruses that includes important emerging human pathogens (Buchmeier
et al., 2007). The Arenaviridae are currently subdivided into two major
subgroups, the OldWorld arenaviruses and the NewWorld arenaviruses
(Clegg, 2002). The OldWorld lineage contains the prototypic arenavirus
lymphocytic choriomeningitis virus (LCMV) and the African arenavirus
Lassa virus (LASV), which is the causative agent of a severe hemorrhagic
fever in humans (McCormick and Fisher-Hoch, 2002). Other African
arenaviruses includeMopeia (MOPV),Mobala (MOBV), and Ippy (IPPYV)
that, so far, have not been associated with human disease (Emonet et al.,
2009). The New World arenaviruses are divided into three Clades, A, B,
and C. Clades A and C include non-pathogenic viruses, whereas the Clade
B viruses Junin (JUNV), Machupo (MACV), Guanarito (GTOV), and Sabia
(SABV)haveemergedas causative agents of severehemorrhagic fevers in
South America (Peters, 2002). Human pathogenic arenaviruses emerge
on average every 2–3 years, as illustrated by the recent identiﬁcation of
two novel arenavirus species associated with fatal hemorrhagic fevers in
humans, Chapare virus in Bolivia and Lujo virus in South Africa. (Briese
et al., 2009; Delgado et al., 2008). Each arenavirus species has as a naturalhost reservoir or a limited number of closely related rodent species, with
the possible exception of Tacaribe virus, which has been only isolated
from the fruit-eating bat Artibeus sp (Emonet et al., 2009). The present
phylogenetic diversity of arenaviruses is likely the result of long-term co-
evolution between viruses and their corresponding host species
reservoir. Human infections occur principally by contact with persis-
tently infected rodents.
Arenaviruses are enveloped negative strand RNA viruses with a
non-lytic life cycle. Their genome consists of two single-stranded RNA
species, a large segment encoding the virus polymerase (L) and a
small zinc ﬁnger motif protein (Z), and a small segment encoding
the virus nucleoprotein (NP) and glycoprotein precursor (GPC)
(Buchmeier et al., 2007; de la Torre, 2009). A crucial step in the
arenavirus life cycle is the biosynthesis of the fusion-active envelope
GP that is essential for host cell attachment and entry. Maturation of
arenavirus GPC requires proteolytic cleavage by the proprotein
convertase (PC) subtilisin kexin isozyme-1 (SKI-1)/Site-1 Protease
(S1P). Processing of GPC by SKI-1/S1P yields the N-terminal GP1, that
is implicated in receptor binding, and the C-terminal transmembrane
GP2, which resembles the fusion-active membrane proximal portions
of other enveloped viral GPs (Beyer et al., 2003; Kunz et al., 2003; Lenz
et al., 2001; Rojek et al., 2008). Processing of arenavirus GPC by SKI-1/
S1P is essential for productive infection and viral spread and recent
studies identiﬁed the SKI-1/S1P-dependent GPC processing as a
promising anti-viral strategy to combat arenaviruses (Maisa et al.,
2009; Rojek et al., 2010; Urata et al., 2011).
Table 1
SKI-1/S1P recognition sites found in cellular and viral substrates. Sequences of cleavage
sites of viral and cellular precursor proteins cleaved by SKI-1/S1P are given (amino acid,
one letter code). Viral substrates derived from GPCs of Old World arenaviruses and the
three clades of New World arenaviruses (Clades A, B, and C) are shown. Also included
are cellular substrates. Arrow indicates where processing takes place.
Classiﬁcation Precursor
protein
Cleavage site sequence
P5 P3′ P1P1′ P3
Viral
substrates
Old World LASV S R R L L↓G T F
LCMV T R R L A↓G T F
LCMV T R R L S↓G T F
MOPV S R R L L↓G T F
MOPV S R R L L↓G L F
IPPYV S R R L M↓S T F
MOBV S R R L M↓G T F
New
World
CladeA PICV S R K L L↓G F F
WWAV S R T L K↓S F F
Clade B JUNV R R S L K↓A F F
MACV E R S L K↓A F F
TACV G R T L K↓A F F
AMPV K R R P L↓A F F
GTOV G R K P L↓A F F
North American
arenavirus
P R S L K↓S F F
North American
arenavirus
A R S L K↓A F F
CHAV L R R L Q↓G V F
SABV S R R P L↓G I F
Clade C LATV T R R L Q↓A F L
OLVV T R R L Q↓A F L
Cellular
substrates
hS1P — Site B F R S L K↓Y A E
hS1P — Site C S R R L L↓R A I
hS1P — Site B′ Q R K V F↓R S L
hpro-BDNF S R G L T↓S L A
hSREBP2 G R S V L↓S F E
hSREBP1a G R N V L↓G T E
hATF6 R R H L L↓G F S
hCREBH S R T L H↓N D A
hCREB4 S R N I L↓T H K
hOASIS S R S L L↓F Y D
hLuman S R Q L R↓A L P
hBBF2H7 S R N L L↓I Y E
19A. Pasquato et al. / Virology 417 (2011) 18–26SKI-1/S1P is an endoplasmic reticulum (ER)/cis-medial Golgi
membrane-anchored serine protease (Sakai et al., 1998; Seidah et al.,
1999). Initially synthesized as an inactive precursor of 1052 amino
acids, the primary structure of SKI-1/S1P consists of a signal peptide, an
N-terminal prodomain, followedby the catalytic domain, andaP-domain
containing a cytokine receptor-like motif (CRM). The transmembrane
domain of SKI-1/S1P is followed by a basic cytosolic tail (amino acids
1023–1052). Upon translocation into the ER, SKI-1/S1P undergoes
autocatalytic cleavage at three processing sites (B, B′, and C) to generate
the active form (Toure et al., 2000; Elagoz et al., 2002). A signiﬁcant
proportion of membrane-bound SKI-1/S1P undergoes autocatalytic
cleavage of its ectodomain, resulting in shedding and release of the
protease as a soluble protein (Elagoz et al., 2002). In contrast to other
basic mammalian PCs, that cleave at the motif (K/R)-(X)n-(K/R)
[n=0,2,4,6; X = any amino acid except Cys], SKI-1/S1P recognizes
hydrophobic consensus sequences R-X-(hydrophobic)-X↓ (Pasquato
et al., 2006). Despite its broad consensus sequence, SKI-1/S1P exhibits
exquisite substrate speciﬁcity and is involved in proteolytic processing of
a deﬁned set of cellular proteins. SKI-1/S1P was shown to cleave brain
derived neurotrophic factor (BDNF) precursor protein (Seidah et al.,
1999) and plays a key role in regulation of lipid metabolism and
cholesterol synthesis through the processing of the membrane-associ-
ated transcription factors sterol regulatory element-binding proteins
SREBP-1 and SREBP-2 (Brown and Goldstein, 1997; Sakai et al., 1998).
Another cellular substrate of SKI-1/S1P is the activating transcription
factor 6 (ATF6), which is a key player in the cellular response to ER stress
(Lenz et al., 2000). Cellular and viral substrates generally share an R-X-
(hydrophobic)-X↓ consensus sequence (Table1).However, thepresumed
SKI-1/S1P processing sites found in GPCs of arenaviruses of different
Clades show remarkable diversity, likely as a result of divergent
evolution. Considering the importance of GPC processing by SKI-1/S1P
for arenavirus infection and its promise as target for future anti-viral
therapeutics, the molecular basis of the recognition of viral substrates by
SKI-1/S1P is of great importance. In the present study we systematically
investigated the ability of human SKI-1/S1P to cleave peptides derived
from the GPC processing sites of different arenaviruses and compared
them to the cellular substrates ATF6 and SREBP2. Our results reveal
remarkable differences between the SKI-1/S1P processing of arenaviral
and cellular substrates on the one hand and GPC-derived peptides
derived from arenaviruses of different Clades on the other hand.
Results
Design of substrate peptides derived from arenavirus GPCs and cellular
SKI-1/S1P substrates
For our systematic comparative study of the SKI-1/S1P processing of
peptides derived from the cleavage sites of different arenavirus GPCs
and cellular substrates, we employed a reliable and quantitative
biochemical assay based on ﬂuorogenic peptides. This well-controlled
in vitro enzymatic activity assay allows quantitative assessment of the
preference of a protease towards speciﬁc peptide sequences represent-
ing processing sites within their target protein. Previous studies
analyzed the activity of SKI-1/S1P using intramolecularly quenched
ﬂuorigenic (IQF) peptides derived from Lassa virus (LASV) GPC, in
particular LASVGP Q-GPC251–263: o-aminobenzoic acid-DIYISRRLL-
GTFTW-3-nitrotyrosine-A-amide (Basak et al., 2002). This peptide was
shown tobe efﬁciently cleaved by SKI-1/S1P. However, since cleavage at
any amide bond may release ﬂuorescence, enzymatic impurities may
give rise to false positive signals (Fig. 1A), which was of considerable
concern in the context of the present study. To address this issue, we
opted for peptidyl methyl coumarides, which are routinely used as
ﬂuorogenic substrates to assess the activity of proprotein convertases
(PCs).Methyl coumaride (MCA)-peptides have the advantage to release
ﬂuorescence only when cleavage takes place at the putative processing
site at the sessile bond C-terminal to MCA (Fig. 1B). Upon processing,7-amino-4-methylcoumarin (AMC) is released. The shift ofﬂuorescence
can be easily detected at 460 nm, thus monitoring the kinetics of
cleavage. Furthermore, the high variability of amino acid at P′ positions
of SKI-1/S1P recognition sites (Table 1), ranging from hydrophobic/
aromatic to hydrophilic/basic, suggests that P1′–P3′ may not strictly
require speciﬁc characteristics. Thus, the MCA aromatic group should
not drastically affect substrate–enzyme recognition. Envelope GPCs of
arenaviruses derived from different Clades and cellular SKI-1/S1P
substrates were taken as template to generate a series of MCA-peptides
(Table 2). For our studies we chose peptides derived from the GPC
processing sites of the African arenaviruses LASV,MOBV, andMOPV. For
the South American arenaviruses, we selected peptides derived from
Pichinde virus (PICV) belonging to Clade A, and Oliveros (OLVV) from
Clade C. To represent the two major sub-groups of the more complex
Clade B, we chose peptides derived from the GPCs of TACV and JUNV on
the one hand and peptides derived from the pathogenic GTOV and its
non-pathogenic relative Amapari virus (AMPV) on the other hand. The
recognition sequenceRRLL found in theGPCs of theAfrican arenaviruses
LASV andMOPV is identical to the RRLL site found in site C of SKI-1/S1P
autoprocessing (Elagoz et al., 2002; Lenz et al., 2001; Seidah et al., 1999),
whereas the recognition sites derived from the other selected
arenavirus GPCs contain a number of amino acid substitutions
generating a remarkable diversity (Table 1). Our study further included
MCA-peptides derived from the SKI-1/S1P processing site of human
SREBP2 andATF6 (Table 2). In addition to peptides corresponding to the
minimal recognition sequence containing amino acids P1–P4, we also
designed longer substrates containing residues upstreamof P4 to assess
their potential role in SKI-1/S1P recognition.
Fig. 1. Schematic representation of ﬂuorogenic substrates cleavage. (A) Intramolecular quenched ﬂuorescence (IQF) peptides: upon cleavage at any position of quenched peptides a
shift of ﬂuorescence is detectable; (B) MCA peptides: only cleavage between the C-terminal amino acid and the MCA group of MCA peptides results in a ﬂuorescence shift.
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Previous studies on the enzymatic function of SKI-1/S1P used
concentrated supernatants from cells over-expressing a recombinant
soluble form of the protease as a source of active enzyme. The use of
enriched cell supernatants instead of puriﬁed enzyme is a necessity due
to a loss of enzymatic activity during puriﬁcation (Pasquato et al., 2006).
Moreover, SKI-1/S1P shows unique substrate speciﬁcity among cellular
PCs and its activity can thus be easily discriminated from possible
contaminations by other proteases. For the production of recombinant
soluble human SKI-1/S1P, we generated HEK293 cell lines stably
transfected with a previously described truncated form of the protease
(ending just before the transmembrane domain, BTMD), SKI-1/S1P-
BTMD, which fully retains enzymatic activity and speciﬁcity (Elagoz
et al., 2002). Clonal HEK293 stable lines transfected with SKI-1/S1P-
BTMD were generated as described in Materials and methods.
Conditioned cell supernatant was characterized to assess the presence
of enzymatic impurities, which could result in detection of activities
unrelated to SKI-1/S1P. For this purpose, we incubated the conditioned
medium with either the commercially available furin-like substrate
pyroglutamic (Pyr)-RTKR-MCAandAc-YISRRLL-MCA,which is basedon
a previously described LASVGPC-derived SKI-1/S1P substrate (Pasquato
et al., 2006).As expected, Ac-YISRRLL-MCAwas efﬁciently cleaved in the
presence of cell supernatants enriched in SKI-1/S1P-BTMD, but much
less so by control supernatants, in line with previous studies (Pasquato
et al., 2006). However, we also observed processing of Pyr-RTKR-MCA,
indicating the presence of furin-like activity in our supernatants, which
could be blocked quantitatively by the furin inhibitor Dec-RVKR-cmk,
conﬁrming the furin-like nature of the contamination (data not shown).
Since furin-like proteases and SKI-1/S1P differ markedly in their
substrate speciﬁcity (Seidah et al., 1999) and furin is not implicated in
the processing of arenavirus GPCs (Rojek et al., 2010), these activities
can be clearly distinguished, allowing the use of conditioned cell
supernatant enriched in SKI-1/S1P-BTMD as a source of enzyme. How-
ever, the presence of enzymatic impurities able to cleave unspeciﬁcally
any substrate and thus releasing MCA independently from SKI-1/S1P
activity remained a concern. To address this issue, we modiﬁed our
currently best SKI-1/S1P substrate, the ﬂuorigenic peptide Ac-YISRRLL-MCA derived from LASV GPC, by introducing a point mutation in the
highly conserved Arg residue P4, resulting in the peptide Ac-YISARLL-
MCA. ReplacementofArg at P4 by any other aminoacid abolished SKI-1/
S1P-mediated processing (Lenz et al., 2000), rendering Ac-YISARLL-
MCA non-cleavable by SKI-1/S1P, as shown in Fig. 2. If unspeciﬁc
contaminants were present in the enzymatic crude preparation, these
would likely process both SKI-1/S1P substrates and Ac-YISARLL-MCA.
Therefore, before any experimentwas performed, conditionedmedium
was tested and used only if it tested negative against the Ac-YISARLL-
MCA substrate.
Differential recognition of arenavirus GPC-derived peptide substrates by
SKI-1/S1P
To assess processing of our substrates by SKI-1/S1P, we employed
previously optimized conditions (Pasquato et al., 2006) and per-
formed the assay at pH 7.5 as well as pH 6.2 to mimic the different pH
conditions along the secretory pathways of cells, including endoplas-
mic reticulum (ER) and cis/medial Golgi where SKI-1/S1P is active
(Cheng et al., 1999a; Elagoz et al., 2002; Pullikotil et al., 2007; Toure
et al., 2000). Kinetic parameters of substrate cleavage were deter-
mined by ﬁtting the Michaelis–Menten equations to the initial rate vs
concentration data and extrapolating to estimate the apparent Vmax
(Vmax(app)) and Km (Km(app)) values (for details see Materials and
methods). In line with previous studies, substrates derived from
the GPC of LASV showed good substrate properties at pH 7.5 with a
Vmax(app)/Km(app) of 11.2 RFU−1 s μM−1 for the 7mer Ac-YISRRLL-
MCA (Table 3). Peptides derived from the GPCs of the related African
virusesMOPV, IPPY, andMOBVwere also cleavedwell, albeit with 5–10
fold less efﬁciency. Interestingly, comparison between the closely
related sequences derived from the GPCs of LASV and MOPV, that
both contain the RRLL recognition sequence, revealed that substitution
of Ile by Phe at position P8 markedly reduced Vmax(app)/Km(app) ratio by
about 2-fold (4.7 vs 2.3), indicating a role of residues upstream of the
RRLL consensus sequence in SKI-1/S1P recognition.
While peptide substrates derived from African arenaviruses were
generally good substrates for SKI-1/S1P in vitro, the situation with the
New World arenaviruses was more complex. When compared to the
Table 2
Synthetic ﬂuorogenic substrates used in this study. Sequences are given using one letter
code; Ac = acetyl; MCA, 7-Amino-4methyl-coumaride. Peptide sequence derivation is
indicated with reference to the GenBank code. Bold underlined amino acids indicate
point mutations with respect to the wild type sequence.
Viral substrates
Name Sequence
New World — Clade A
PICV GPC (ABU39904.1)
Pic1 Ac-YSSVSRKLL-MCA
Pic2 Ac-SSVSRKLL-MCA
Pic3 Ac-RKLL-MCA
New World — Clade B
GTOV GPC (NP_899210.1)
Gua1 Ac-YLVGRKPL-MCA
Gua2 Ac-LVGRKPL-MCA
Gua3 Ac-YVGRKPL-MCA
Gua4 Ac-RKPL-MCA
AMPV GPC (AAN32967.1)
Ama1 Ac-SLPKRRPL-MCA
Ama2 Ac-RRPL-MCA
TACV virus GPC (NP_694849.1)
Tac1 Ac-QKSIAVGRTLK-MCA
Tac2 Ac-IAVGRTLK-MCA
Tac3 Ac-RTLK-MCA
JUNV GPC (ACY70854.1)
Jun1 Ac-QLPRRSLK-MCA
Jun2 Ac-RSLK-MCA
New World — Clade C
OLVV GPC (YP_001649210.1)
LATV GPC (YP_001936021)
Lat1 Ac-SFITRRLQ-MCA
Lat2 Ac-RRLQ-MCA
Old World
IPPYV GPC (YP_516230.1)
MOBV GPC (YP_516226.1)
Ipp1 Ac-IYISRRLM-MCA
LASV GPC (AAT49010.1)
Las1 Ac-IYISRRLL-MCA
Las2 Ac-YISRRLL-MCA
Las3 Ac-RRLL-MCA
MOPV GPC (YP_170709.1)
Mop1 Ac-FYISRRLL-MCA
Cellular substrates
Name Sequence
hSREBP-2 (NP_004590.2)
Sre1 Ac-SGSGRSVL-MCA
Sre2 Ac-RSVL-MCA
hATF6 (BAF83187.1)
Atf1 Ac-ANQRRHLL-MCA
Atf2 Ac-RHLL-MCA
hS1P (NP_003782.1)
S1P1 Ac-VFRSLK-MCA
Fig. 2. Kinetics of cleavage of Ac-YISRRLL-MCA and Ac-YISARLL-MCA. Conditioned
medium containing soluble SKI-1/S1P (20 μl) was incubated with either 10 μM Ac-
YISRRLL-MCA or Ac-YISARLL-MCA in pH 7.5 buffer solution and released ﬂuorescent
AMC (RFU) monitored over time (min).
21A. Pasquato et al. / Virology 417 (2011) 18–26RRLL recognition sequence of LASV, the sequence derived from GPC of
the prototypic Clade A virus PICV (RKLL), contains a replacement of
Argwith Lys at position P3, which had a small (40%) negative effect on
the ability of SKI-1/S1P to recognize and cleave the corresponding
peptide substrates (Table 3). However, unlike the case of LASV GPC-
derived peptides (Pasquato et al., 2006; Table 3), extended peptides
mimicking the PICV GPC cleavage site were rather poor substrates,
suggesting that residues preceding the recognition site (P1–P4) have
a negative effect on processing.
Marked differences were found among substrates derived from
GPCs of Clade B viruses. Peptides mimicking the GPC of TACV were
found to be excellent in vitro substrates. For JUNV, the 4mer substrate
was cleaved very efﬁciently and, analogously to PICV, residues
preceding the P1–P4 stretch had a negative effect. Interestingly, theset of peptides derived from the Clade B NewWorld viruses GTOV and
AMPV showed no signiﬁcant cleavage under the conditions tested
(Table 3).
Recent phylogenetic analysis revealed a close relationship of the
GPC sequences of the Clade C New World arenaviruses Latino (LATV)
and Oliveros (OLIV) with the GPCs of arenaviruses from the OldWorld
(Emonet et al., 2009) that is also reﬂected by the use of a common
cellular receptor (Spiropoulou et al., 2002). However, despite the
overall similarity between GPCs of Clade C NewWorld and Old World
viruses at the level of sequence and receptor use, substrate peptides
derived from the GPCs of LATV and OLIV were cleaved inefﬁciently
(Table 3). The glutamine at position P1 may account for the poor
cleavability, given that this is the only difference between the Ac-
RRLL-MCA (LASV) and Ac-RRLQ-MCA (LATV/OLIV) substrates. Under
more acidic conditions (pH 6.2), we observed a general decrease of
Vmax(app)/Km(app) values with substrates derived from the GPCs of
LASV, TACV, MOPV, and OLIV being the most affected (Table 3).
However, the overall pattern of substrate preference was consistent
under the two pH conditions (Table 3). The only substrate which does
not follow this general rule is Ac-IYISRRLL-MCA and we hypothesize
that this might be linked to the physical–chemical properties of the
C-terminal group. In fact, replacement of the C-terminal acetyl with
succinyl reverses the effect (Pasquato et al., 2006, data not shown).
Next, we conducted a comparative study including peptides
derived from cellular SKI-1/S1P substrates, namely SREBP2 and
ATF6. Similar to the sequences derived from some New World
viruses, the ATF6 derived peptide Ac-RHLL-MCA showed a rather low
Vmax(app)/Km(app) (Table 3), indicating poor processing. The more
extended substrate peptide ATF6 Ac-ANQRRHLL-MCA was processed
better than the shorter 4mer, although still inefﬁciently. Short
sequences mimicking the GPC processing site of human SREBP2
behaved similarly to ATF6-derived peptides. Analysis of Vmax(app) and
Km(app) revealed surprisingly low afﬁnity of SKI-1/S1P for both SREBP2
and ATF6-derived substrates with a Km(app) of 400 μM and 96 μM,
respectively (Table 3). Under more acidic pH (6.2), the ATF6 and
SREBP2 showed higher Vmax(app)/Km(app) values, but remained
relatively poor substrates. Possibly, more extended sequences or
other factors present in the whole proteins are required to enhance in
vitro cleavability (Cheng et al., 1999b).
The cyclic C*IYISRRLLC* peptide is a speciﬁc SKI-1/S1P inhibitor in vitro
Peptide-derived SKI-1/S1P inhibitors, including the decanoylated
chloromethylketone peptide dec-RRLL-cmk lack speciﬁcity in vitro as
they also block basic amino acid speciﬁc proprotein convertases
(Pasquato et al., 2006). Since our present study highlighted the
Table 3
Kinetic parameters for substrates tested. In vitro enzymatic parameters Vmax(app), Km(app), and Vmax(app)/Km(app) at pH 6.2 and 7.5 for each ﬂuorogenic substrates calculated as
described in Materials and methods. Values are means (n=3, ±SD); NC, not calculable. Substrates are gathered together, according to their derivation (top, Old World arenavirus;
middle, New World arenavirus; bottom, cellular).
pH 7.5 pH 6.2
Derivation
(GPC)
Sequence Km(app)
[μM]
Vmax(app)
[RFU s−1]
Vmax(app)/Km(app)
[RFU−1 s μM−1]
Km(app)
[μM]
Vmax(app)
[RFU s−1]
Vmax(app)/Km(app)
[RFU−1 s μM−1]
Old World arenavirus LASV Ac-IYISRRLL-MCA 5.0±1.0 23.3±1.0 4.7 1.1±0.5 14.8±1.3 13.7
LASV Ac-YISRRLL-MCA 2.7±0.2 30.2±0.6 11.2 4.5±0.9 27.4±1.6 6.1
LASV/MOPV/S1P Ac-RRLL-MCA 21.8±8.4 30.3±3.2 1.4 23.2±6.0 24.7±1.8 1.1
MOPV Ac-FYISRRLL-MCA 6.0±2.8 13.7±1.4 2.3 10.8±0.9 13.8±0.3 1.2
IPPYV/MOBV Ac-IYISRRLM-MCA 8.4±1.9 14.5±0.8 1.7 6.06±2.7 9.7±0.8 1.6
OLVV/LATV Ac-SFITRRLQ-MCA 1.1±0.5 1.5±1.3 1.3 27.1±19.1 3.5±0.7 0.1
OLVV/LATV Ac-RRLQ-MCA 46.6±8.9 4.5±0.3 0.1 50.1±22.1 4.9±0.7 0.1
New World arenavirus PICV Ac-YSSVSRKLL-MCA 35.5±1.7 21.9±0.4 0.7 18.5±3.8 20.4±1.2 1.1
PICV Ac-SSVSRKLL-MCA 37.0±7.6 29.5±2.1 0.8 35.5±1.7 21.9±0.4 0.6
PICV Ac-RKLL-MCA 29.7±5.3 32.0±1.5 1.1 36.8±6.7 26.4±1.4 0.7
JUNV Ac-QLPRRSLK-MCA 33.7±3.6 33.4±1.1 1.0 64.88±9.0 9.45±0.6 0.1
JUNV Ac-RSLK-MCA 43.9±11.0 53.4±5.5 1.2 57.93±6.1 12.6±0.5 0.2
TACV Ac-QKSIAVGRTLK-MCA 9.7±2.4 45.7±2.1 4.7 16.4±3.8 36.1±1.9 2.2
TACV Ac-IAVGRTLK-NCA 6.0±1.2 50.1±1.8 8.3 5.1±1.2 38.1±1.9 7.4
TACV Ac-RTLK-MCA 12.0±1.6 62.7±1.6 5.2 31.7±7.6 43.2±2.9 1.4
GTQV Ac-YLVGRKPL-MCA NC NC NC NC
GTQV Ac-LVGRKPL-MCA NC NC NC NC
GTOV Ac-YVGRKPL-MCA NC NC NC NC
GTOV Ac-RKPL-MCA NC NC NC NC
AMPV Ac-SLPKRRPL-MCA NC NC NC NC
AMPV Ac-RRPL-MCA NC NC NC NC
Cellular S1P Ac-VFRSLK-MCA 8.1±26.8 26.8±1.5 3.3 12.7±1.6 22.2±0.6 1.7
SREBP2 Ac-SGSGRSVL-MCA 87.0±19.5 4.9±0.5 0.1 443.0±330.1 14.6±8.3 0.03
SREBP2 Ac-RSVL-MCA 14.1±10.9 4.0±0.9 0.3 5.3±4.4 2.3±0.4 0.4
ATF6 Ac-ANQRRHLL-MCA 96.0±30.3 42.1±6.5 0.4 135.7±20.0 66.4±5.4 0.5
ATF6 Ac-RHLL-MCA 300.0±32.0 24.4±1.8 0.1 320.0±115.0 43.6±11.0 0.1
22 A. Pasquato et al. / Virology 417 (2011) 18–26importance of residues N-terminal of the RRLL site for efﬁcient
recognition of LASV GPC and other substrates, we used this
information for the rational design of novel inhibitor peptides speciﬁc
for SKI-1/S1P. Speciﬁcally, we synthesized two cyclic decapeptides
mimicking P1–P8 of LASV GPC and ATF6 (Fig. 3). In order to obtain
circular peptides, the P1′ residue was replaced by a Cys engaged in a
disulphide bridge with another Cystine at P9 position. As Cys residues
are rarely found within sequences cleaved by proprotein convertases
(Remacle et al., 2008), we expected that this residue would not be
accepted by SKI-1/S1P as well, resulting in uncleavable peptides. On
the other hand, since the recognition sites from LASV GPC
*CIYISRRLLC* (C1) or ATF6 *CANQRRHLLC* (C2) are present, the
molecule should keep some afﬁnity towards the catalytic pocket. To
increase enzyme–substrate interaction, we forced the sequence to
assume a cyclic structure, possibly mimicking the natural loop where
the consensus sequence is actually exposed. SKI-1/S1P was pre-
incubated at room temperature with increasing concentrations of C1
and C2 and tested for their ability to cleave our best substrate, the
LASV GPC-derived Ac-YISRRLL-MCA. The ATF6-derived C2 peptide did
not inhibit soluble SKI-1/S1P at any of the concentrations used
(Fig. 4A). On the contrary, the LASV GPC-derived C1 peptide was an
effective inhibitor of SKI-1/S1P in the micromolar range, with a
calculated IC50 of 22.3 μM (Fig. 4B). We also conﬁrmed that C1 did notFig. 3. The inhibitor peptides C1 and C2. Primary sequence (amino acids, one letter
code) of the C1 and C2 peptides are shown. Note that the Cys residues are linked by
disulphide bonds, resulting in a cyclic peptide.quench the released AMC bymonitoring ﬂuorescence of ﬁxed amount
of free AMC titrated with increasing amount of inhibitor peptide (data
not shown).
The mechanisms of action of C1 may involve direct competition of
the inhibitor with the ﬂuorogenic substrate for the catalytic pocket.
Indeed, the Km of Ac-YISRRLL-MCA decreased more than two fold in
the presence of 20 μMof the C1 cyclic compound (data not shown). To
evaluate the speciﬁcity of C1, its inhibitory potency was then tested
against commercial recombinant soluble furin, representative mem-
ber of basic amino acid speciﬁc proprotein convertases. Our results
showed that C1 did not inhibit furin up to 100 μM (Fig. 4C). We next
tested the potency of C1 against LCMV GPC processing in human
HEK293 cells. To render the peptide delivery more efﬁcient, we
employed a cell penetrating peptide (CPP) (Morris et al., 2001).
Brieﬂy, HEK293 cells were transfected with recombinant LASV GPC
containing a C-terminal FLAG tag (Rojek et al., 2008) using
Lipofectamine 2000. After 4 h, cells were treated with 50 μM of the
C1 peptide with or without CPP. High concentrations were chosen
since C1 was not designed to be cell permeable, differently from other
inhibitors of intracellular proteases. After 48 h, cells were lysed and
GPC processing monitored by Western blot analysis. As shown in
Fig. 4D, treatment with the peptide C1 resulted in a signiﬁcant
reduction of LASV GPC processing (47% C1 50 μM and 60% C1 50 μM
+CPP), whereas the CPP alone did not affect GPC processing. Notably,
addition of CPP increased the potency of C1 only slightly, indicating
signiﬁcant cell penetration by the peptide alone. Taken together, our
data indicate that the LASV GPC-derived cyclic C1 peptide is the ﬁrst
peptide-derived SKI-1/S1P inhibitor that shows speciﬁcity in vitro and
signiﬁcantly inhibits the cellular LASV GPC processing by endogenous
human SKI-1/S1P.
Discussion
In the present study, we quantitatively assessed the ability of
human SKI-1/S1P to cleave peptides derived from the processing sites
Fig. 4. Inhibitory effects of the C1 and C2 peptides. (A, B) Inhibition of recombinant SKI-1/S1P activity in vitro: Soluble recombinant SKI-1/S1P was pre-incubated with the indicated
concentrations of inhibitors C2 (A, RFU at 6 h) and C1 (B, dose response plot; initial rate vs inhibitor concentration) or DMSO (CTRL) for 20 min at room temperature, followed by
addition of the substrate Ac-YISRRLL-MCA (20 μM). (C) Inhibition of the furin-mediated cleavage of Pyr-RTKR-MCA by C1: initial rate [RFU/s] plotted against C1 concentrations.
(D) C1 inhibits processing of LCMV GPC: HEK293 cells were transfected with LCMV GPC. Four hours post-infection, cells were treated with C1 (50 μM), C1 (50 μM)+cell penetrating
peptide (CPP) (50 μM), CPP (50 μM), or DMSO solvent control. After 48 h, cells were lyzed, total protein separated by SDS-PAGE and blotted to nitrocellulose. Blots were probed with
mAb 83.6 to arenavirus GP2 using a HRP-conjugated secondary antibody and enhanced chemiluminescence (ECL) for detection. Uncleaved precursor (GP-C), unglycosylated (uGPC)
and cleaved viral envelope glycoprotein (GP-2) are indicated. For normalization, α-tubulin (Tub) was detected. Apparent molecular masses are indicated.
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indicated that human SKI-1/S1P appears to strongly discriminate
among substrate peptides derived from the recognition sites of
different arenavirus GPCs. The proteinase seems to have a strong
preference for peptide substrates that mimic the SKI-1/S1P autoproces-
sing B-site (RSLK) or C-site (RRLL). In contrast, peptides derived from
the cellular targets ATF6 and SREBP2were rather poor substrates. Based
on the results of our study, we designed and evaluated a novel and
unique cyclic peptide inhibitor able to speciﬁcally block the SKI-1/S1P
activity.
Arenaviruses are carried in nature by one or several rodent host
reservoir species. The virus is maintained in the rodent population by
vertical transmission, i.e. congenital infection from the infected mother
to the fetus in utero. The absence of a speciﬁc anti-viral immune
response results in a lifelong persistent productive viral infection. The
current large genetic and structural diversity of arenaviruses has likely
been shaped by co-evolution of each virus with its rodent reservoir
species, whereas humans are accidental hosts representing a dead end
for the virus. Since previous studies demonstrated a high degree of
structural and functional conservation between human and rodent SKI-
1/S1P, the ﬁndings of our study may not only be relevant for the virus–
host cell interaction in humans, but likely also in their rodent hosts.
Using a reliable and quantitative assay, we systematically investi-
gated the SKI-1/S1P processing of a large panel of peptides derived from
arenavirus GPCs and cellular substrates. Our study revealed a strongpreference of SKI-1/S1P for arenaviral GPC recognition sequences that
resemble its autoprocessing sites (Table 4). Interestingly, the processing
sites found in GPCs of Old World arenaviruses like LASV, MOPV, and
MOBV resemble the sequence RRLL↓ of the C autoprocessing site of SKI-
1/S1P, whereas the Clade B NewWorld virus GPCs mimic the sequence
RT/SLK↓ present in the B autoprocessing site. Themimicry of two rather
different sequence motifs involved in SKI-1/S1P autoprocessing by Old
World andNewWorld viruses suggests convergent evolution towards a
common GPC processing mechanism resembling autoprocessing. The
similarityof LASVGPC cleavagewithSKI-1/S1Pautoprocessing is further
supported by the fact that cleavage of LASV GPC by SKI-1/S1P occurs
already in the ER (Beyer et al., 2003; Lenz et al., 2001), whereas cellular
substrates like ATF6 and SREBP2 undergo cleavage in the Golgi (Lenz
et al., 2000; Sakai et al., 1998). Interestingly, sequences derived from
GPC of the prototypic LCMV that is cleaved in the Golgi (Beyer et al.,
2003)were poor in vitro substrates (Pasquato et al., 2006). The ability of
GPCs from phylogenetically distant arenaviruses to mimic SKI-1/S1P
autoprocessing suggests a selective advantage of such a mechanism.
One possibility is that GPC cleavage by an “autoprocessing-like”
mechanism in the ER avoids direct interference of viral GPC with SKI-
1/S1P's processing of endogenous substrates like ATF6 and SREBP2 in
the Golgi. Such amechanismmay render GPC processingmore efﬁcient
and limiting the negative impact of the virus on the host cell.
While arenavirus GPC-derived peptides mimicking autoprocessing
sites were efﬁciently processed in our assay, deviating sequences
Table 4
SKI-1/S1P has a preference for viral substrates that mimic its B and C autoprocessing
sites. For details please see text.
JUNV D2CFS1 R R S L K↓A F F S1P Site B resembling
In vitro cleavableNorth American
arenavirus
B2KSC8 A R S L K↓A F F
North American
arenavirus
B2KSC5 P R S L K↓S F F
MACV Q6IVT5 E R S L K↓A F F
TACV P18141 G R T L K↓A F F
WWAV Q8B118 S R T L K↓S F F
LASV Q6GWR6 S R R L L↓G T F S1P Site C containing
Good in vitro cleavabilityMOPV Q5S586 S R R L L↓G T F
MOPV Q27YF0 S R R L L↓G L F
PICV Q9YTW9 S R K L L↓G F F S1P Site C resembling
Good in vitro cleavabilityMOBV Q2A069 S R R L M↓G T F
IPPYV Q27YE4 S R R L M↓S T F
LATV Q8B121 T R R L Q↓A F L S1P Site C resembling
Poor in vitro cleavabilityOLVV Q84168 T R R L Q↓A F L
CHAV Q8AYW1 L R R L Q↓G V F
LCMV C3VVN0 T R R L A↓G T F
LCMV Q9QDK7 T R R L S↓G T F
GTOV Q8AYW1 G R K P L↓A F F ?
Poor in vitro cleavabilitySABV Q90037 S R R P L↓G I F
AMPV Q90037 K R R P L↓A F F
hS1P — Site B F R S L K↓Y A E
hS1P — Site C S R R L L↓R A I
hS1P — Site B′ Q R K V F↓R S L
24 A. Pasquato et al. / Virology 417 (2011) 18–26found for example in the Clade B viruses GTOV and AMPV, as well as
the Clade C viruses LATV and OLIV were poor substrates (Table 4). The
inefﬁcient processing of peptides derived from GTOV GPC seems
surprising, considering the efﬁcient replication of the virus in mam-
malian cells and its virulence in humans (Peters, 2002). Moreover,
when expressed in recombinant form, GTOV GPC is efﬁciently
processed in human and rodent cells (Rojek et al., 2008). We can
currently not rule out that our assay conditions did not adequately
mimic the pH and redox potential of the cellular compartment where
GTOV GPC undergoes processing. However, the discrepancy between
processing of GTOV GPC-derived peptides by SKI-1/S1P in our
biochemical assay and cleavage of recombinant full-length GPC in
cells suggests that GPC residues outside of the peptides designed for
our studies are critical determinants for themolecular recognition and
processing of GTOV GPC. Thus, cleavage in the whole protein could be
strongly inﬂuenced by factors not present in the peptide based
system, a notion supported by other data from published reports and
the present study (see below). In contrast to GTOV, the poor substrate
qualities of the AMPV GPC-derived peptides used in this study are in
line with the inefﬁcient processing of AMPV GPC in human cells
(Rojek et al., 2008). Inefﬁcient maturation of GPC may thus contribute
to the low pathogenic potential of AMPV in humans.
Our present studies conﬁrmed and extended previous ﬁndings that
reported a role for residues outside the actual SKI-1/S1P recognition site
for viral GPCprocessing (Pasquato et al., 2006). Speciﬁcally,weprovided
evidence that residues N-terminal of the SKI-1/S1P recognition site are
crucial for efﬁcient processing of a number of viral substrates. Thesedata
suggest that the catalytic pocket of SKI-1/S1P may be unusually large
and that key residues upstream of the actual processing site contribute
to critical molecular contacts affecting the kinetics of cleavage.
Considering the important function of SKI-1/S1P in normal cell
physiology and its potential as a drug target for anti-arenaviral
therapy, high throughput small molecule screens for inhibitors are of
great relevance (Hawkins et al., 2008; Hay et al., 2007). Based on the
results of our study, we propose the use of our novel MCA peptides
derived from LASV and TACV GPC as novel substrates for high-
throughput screening (HTS) approaches to identify novel small
molecule inhibitors for SKI-1/S1P. According to our experiences
these MCA peptides are at least equivalent in their kinetic propertiesto conventional IQF substrates, but more speciﬁc and cost effective
and thus highly suitable for highly sensitive HTS analyses.
Lastly, our studies provided the basis for the design of a novel
speciﬁc peptide inhibitor for SKI-1/S1P, the LASV GPC-derived circular
peptide C1 (*CIYISRRLLC*). A ﬁrst evaluation, C1 demonstrated an
unprecedented speciﬁcity for SKI-1/S1P in an enzymatic assay in vitro,
as well as speciﬁc inhibition of LASV GPC processing in human cells by
endogenous SKI-1/S1P. Despite its relatively high IC50 on target in
cells that makes it an unlikely candidate for anti-viral drug
development, due to its speciﬁcity, the C1 peptide will be valuable
for experimental purposes, where a selective SKI-1/S1P inhibitor is
needed in biochemical assays in vitro.
Materials and methods
Source of recombinant human SKI-1/S1P
Secreted soluble human SKI-1/S1P, lacking the transmembrane
domain and cytosolic tail (SKI-1/S1P-BTMD) and containing a C-
terminal hexa-histidine tag was obtained from stable transfected
Human Embryonic Kidney (HEK) 293 cells. For the generation of
stable HEK293 cell lines producing soluble SKI-1/S1P, the construct
SKI-I/S1P-BTMD pcDNA3-Puro, which contains a puromycin resis-
tance cassette, was linearized and transfected into HEK293H cells,
using lipofectamine (GIBCO BRL). Stable transfectants were selected
by antibiotic treatment using puromycin (1 μg/ml) (GIBCO). After
2 weeks of selection, colonies of stable transfected cells were isolated,
expanded, and tested for transgene expression by Western blot. The
presence of the enzyme in the media was conﬁrmed by Western
blotting. Brieﬂy, media were subjected to SDS-polyacrylamide gel
electrophoresis on 8% gels and proteins blotted onto nitrocellulose
membranes. The anti-penta His (Anti-His Antibody Selector Kit,
Qiagen AG) primary antibody was revealed by horseradish peroxi-
dase-conjugated secondary antibodies (Amersham, Pharmacia Bio-
tech) and Enhanced chemiluminescence (LiteAblot, Euroclone Life
Sciences) according to the manufacturers' instructions. The two lines
with strongest expression were propagated and readapted to serum-
free culture conditions using 293SFMII (GIBCO BRL). Both lines tested
positive for transgene expression after 4 weeks in serum-free culture
and the line with higher expression levels was selected. SKI-1/S1P-
BTMP was produced in high density suspension cultures in 293SFMII.
Supernatant was ﬁltered (0.22 μm) and concentrated. The presence of
active soluble enzymewasmeasured against the Acetyl (Ac)-YISRRLL-
7-Amino-4methyl-coumaride (MCA) (GenScript, custom synthesis)
SKI-1/S1P substrate at pH 7.5, and the absence of unspeciﬁc activities
testedwith the S1P-uncleavable Ac-IYSARLL-MCA peptide (GenScript,
custom synthesis) as described below.
In vitro enzymatic assays
Reactions were carried out in a 100-μl buffer (25 mm Tris–HCl,
25 mmMES, and 1 mm CaCl2 adjusted either to pH 7.5 or 6.2) at room
temperature in 96-well plate format. The reactions contained
increasing concentrations (0.5–200 μM, 2 μl) of MCA peptide (Gen-
Script, custom synthesis) dissolved in dimethyl sulphoxide (DMSO)
and 20 μl of hSKI-1/S1P preparation. Enzymatic activity measure-
ments with MCA-conjugated peptidyl substrates were performed by
measuring the liberated 7-amino-4-methylcoumarin (AMC) with a
TriStar LB 941 multimode microplate spectroﬂuorometer, Berthold
technologies (λex, 360 nm; λem, 460 nm). For measurement of
apparent Vmax and Km kinetic parameters, hSKI-1/S1P (20 μl) was
incubated with increasing concentrations (20–200 μm) of each MCA-
peptide (GenScript, custom synthesis) in 100 μl of buffer in a 96-well
microtiter plate at room temperature under the above conditions.
Vmax and Km values were estimated by Graﬁt Version 6 (Erithacus
Software Ltd., Staines, United Kingdom). The software ﬁts data to the
25A. Pasquato et al. / Virology 417 (2011) 18–26Michaelis–Menten equation, where the rate is plotted as a function of
the concentration of the substrate. Initial estimates are provided by
use of linear ﬁtting using the Scatchard rearrangement. Initial rates
were evaluated for each peptide at different concentrations using the
programMicroWin 2000 Version 4.0 (Mikrotek Laborsysteme GmbH)
based on the linear portion of the curve.In vitro inhibition of Ac-IYIRRLL-MCA processing
Each reaction was carried out in a 100-μl buffer (25 mm Tris–HCl,
25 mmMES, and 1 mm CaCl2 adjusted to pH 7.5) at room temperature.
20 μl of hSKI-1/S1Ppreparationwaspre-incubated in the reaction buffer
with2 μl of either cyclic *CIYISRRLLC* (C1)or cyclic *CANQRRHLLC* (C2)
inhibitor (GenScript, custom synthesis) at different concentrations (0–
200 μl) were incubated 20 min at room temperature before adding
20 μMAc-IYISRRLL-MCA as substrate. Enzymatic activitymeasurements
wereperformedbymeasuring the liberatedAMCgroupwith a TriStar LB
941 multimode microplate spectroﬂuorometer, Berthold technologies
(λex, 360 nm; λem, 460 nm).Determination of in vitro inhibitor constant IC50 values
For measurements of IC50 values, 20 μl hSKI-1/S1P was pre-
incubated with increasing concentrations of either C1 or C2 inhibitor
in 100 μl of buffer in a 96-well microtiter plate at room temperature
under the above conditions. IC50 value was calculated by using GraFit
version 6 software.In vitro inhibition of Pyr-RTKR-MCA processing
Reactions were carried out in a 100-μl buffer (25 mm Tris–HCl,
25 mmMES, and 1 mmCaCl2 adjusted to pH7.5) at room temperature in
96-well plate format. Puriﬁed soluble human furin (BioLabs) was pre-
incubated with increasing concentrations (0.5–200 μM) of either C1 or
C2 inhibitor before measuring released AMC moiety from the furin
substrates Pyroglutamic acid (Pyr)-RTKR-MCA (Peptides International)
with a TriStar LB 941 multimode microplate spectroﬂuorometer,
Berthold technologies (λex, 360 nm; λem, 460 nm).Inhibition of LCMV GPC processing
Five times 105 HEK293 cells/well were seeded in a 12 wells plate
and cultured overnight, resulting in monolayer. Transfections were
performed using plasmids encoding LCMV GPC and Lipofectamin
2000 (Invitrogen) according to the manufacturer's protocols. 4 h post
transfection (p.t.), cells were treated with C1 50 μM or DMSO (2%)
as control. In addition, 50 μM of cell penetrating peptide (CPP,
KETWWETWWTEWSQPKKKRKV) was added to increase drug cell
permeability. 48 h p.t., the total protein was extracted, separated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and
blotted to nitrocellulose. Blots were probed with MAb 83.6 to
arenavirus GP2. Bound primary antibody was detected with HRP-
conjugated secondary antibody and enhanced chemiluminescence.Acknowledgments
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